Home > Newsletters > Washington Drug Letter > High Court Likely to Keep ‘Safe Harbor’ Broad, Aiding Generics, Biosimilars
Washington Drug Letter
Sept. 3, 2012 | Vol. 44 No. 35
High Court Likely to Keep ‘Safe Harbor’ Broad, Aiding Generics, Biosimilars
The country’s highest court is likely to mull Hatch-Waxman’s safe-harbor provision now that the U.S. Court of Appeals for the Federal Circuit has issued contradictory rulings on when the law allows drugmakers to use others’ patents without fear of infringement.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.